Pharmicell Achieves Revenue of 75.6 Billion Won and Operating Profit of 26.3 Billion Won in H1... Simultaneous Growth in Electronic Materials and Bio Businesses

Pharmicell (005690) posted increases in both revenue and operating profit for the first half of this year, driven by growth in its core electronic materials business and improvements in its bio business.

On August 12, Pharmicell announced that its consolidated revenue for the first half of 2026 reached 75.6 billion won, with operating profit at 26.3 billion won. For the second quarter alone, the company achieved revenue of 38.9 billion won and operating profit of 13.2 billion won.

The strong performance in the first half was led by the electronic materials business used in advanced information technology (IT) infrastructure. Additionally, steady revenue generated from the pharmaceutical raw materials segment, such as nucleosides and mPEG, contributed to the company's overall growth.

The bio segment also showed signs of improvement. Revenue increased across stem cell therapy, cosmetics, contract manufacturing organization (CMO), and contract testing businesses, all contributing to better results for the division.

Pharmicell plans to sustain the growth of its core businesses in the second half of the year. The company aims to continuously enhance its competitiveness in the electronic materials sector, while diversifying its business portfolio and expanding its growth base through the enlargement of its bio CMO operations.

A Pharmicell representative stated, "Revenue and operating profit both increased, supported by the growth of our core electronic materials business and the recovery in our bio segment," adding, "We will continue to strengthen the competitiveness of our electronic materials and expand the bio CMO business in the second half to maintain our growth trajectory."

Based on the steady growth of electronic materials and improvements in pharmaceutical raw materials and the bio business, Pharmicell achieved expanded results in the first half of the year. Moving into the second half, the company plans to sustain its upward momentum with a focus on electronic materials and the bio CMO business.

This content was produced with the assistance of AI translation services.